17 August 2018 - Australian cancer patients are being forced to wait up to 18 months for affordable access to life-saving cancer drugs ­because the regulatory system has not kept pace with advancement in immuno-oncology ­treatments.

Pharmaceutical giant Bristol Myers Squibb will argue that point today at a specially ­convened meeting of the Pharmaceutical Benefits Advisory Committee.

BMS will also use the meeting to push a proposed pilot program to cut that waiting period down to about three months.

Read The Australian article